Phase I/II trial of samarium SM-153 lexidronam combined with docetaxel for patients with androgen-independent prostate cancer

Trial Profile

Phase I/II trial of samarium SM-153 lexidronam combined with docetaxel for patients with androgen-independent prostate cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Docetaxel; Prednisone; Samarium-153-SM-lexidronam
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cytogen Corporation
  • Most Recent Events

    • 14 Jun 2007 Status change
    • 06 Jun 2007 Preliminary results on 10 patients reported at ASCO.
    • 05 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top